Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
about
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligaseThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsEndoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cellsGermline stem cell gene PIWIL2 mediates DNA repair through relaxation of chromatinCisplatin and aminoglycoside antibiotics: hearing loss and its prevention.ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy.Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.Photo-cross-linking of XPC-Rad23B to cisplatin-damaged DNA reveals contacts with both strands of the DNA duplex and spans the DNA adduct.Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerNovel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatinTranscriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsBcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation.Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis modelEffect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device.Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticlesRescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling networkDNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesionsFormation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment.Monofunctional and higher-valent platinum anticancer agents.Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity.Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution.Vasculogenic mimicry in small cell lung cancer.Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing.Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.H2AX a promising biomarker for lung cancer: a review.Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder CancerMMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer.ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.Caenorhabditis elegans as a powerful alternative model organism to promote research in genetic toxicology and biomedicine.Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
P2860
Q24304122-6F9E2B15-CAA2-4804-B174-F332BFDF5657Q28066801-B021B789-7B88-4E6E-8014-F5B929454155Q28533746-1D4AFE0C-34BF-4BC8-B340-13E290AB012DQ28593830-B358CC40-EE33-4E6E-BE66-049619C7DDA1Q30447637-F50AF588-E87E-4F20-BCCF-11C2BEAD6A41Q30580553-2AEC2D86-C3A7-4196-99F7-072E5D7885C9Q33482074-107F3327-B411-415E-8726-A243106C9095Q33506479-71C76D79-AF40-49E9-B80F-1F6AFC4DDBCEQ33564338-EC402178-B4D2-4BCD-894A-B543D69EC098Q33612006-27D0FB4B-A409-4E70-B4F6-B9390BA38B85Q33788519-4B3E0F0B-AA5E-4A33-ADE5-AE3DAA81CE1CQ33994331-8A31D771-DE1A-4CEC-BE11-0B642C96F320Q34214639-BFA0D72B-8F0E-4EA9-980C-71C45E08B71CQ34479313-28769731-20D7-47FF-9163-8D23CDE01330Q34562736-5CCA9245-5703-48D5-903E-B226E87474BAQ34722650-8C648528-EC4C-4EB5-ABBD-4A1AE81657F1Q35067924-9757F4E7-FA8F-4FFD-9ADA-0512DC253D57Q35777174-5E906CA5-4B2D-45F3-B2CC-A65C3A9FFE9FQ36594139-CB8A2EE9-02B6-4AC2-8641-33365079BC7BQ36817080-FAC94627-5323-4CA6-9F51-F3A53CECD5FDQ36877212-30ADF7C0-A365-4355-9FDE-CD373AD2D6E6Q36970889-5CA131A6-1322-448D-B740-4F4BBA82FCF6Q36994777-259C02DC-B77B-4084-BAAA-461181951116Q37069571-8B8B1D05-6F83-425D-9AAA-3BECA94077EBQ37185747-4D777393-6B1F-4F75-9522-68DF182B6E44Q37282213-AE04F5BE-B35D-470B-8B4F-84DE8640B631Q37299627-64D63A23-5039-4F46-A718-CB238EB6A2E5Q37309473-28F754CF-B508-420D-B95B-C49338E4F100Q37346994-BF41EAEE-ED26-42CF-ADA3-2346BBBC5354Q37408684-ED779173-BCEC-4811-AB63-B209FA9645E5Q37566689-1F6136B9-03B4-4AA7-A010-02A66DAD9BD5Q37682756-2BD471CC-F4FC-40AB-AA10-31C653D125A0Q38155902-9ED6D470-B266-4E25-BEAF-20312DBF6507Q38697331-79F7EE54-E18A-4AEC-A2C0-50F023708B2AQ38721568-1CCE1FB4-F4BD-41A5-85D5-5A592F3375DCQ38734519-9781C373-CCFA-431A-856D-C021F1B232EDQ38798948-233510DD-92F8-44FC-9992-D611E7877B85Q38829177-9FAF5965-CE96-4097-83BA-B81C5FD765CBQ38904492-C307C12F-1FE7-462F-8020-B2F64DBC1C61Q39540757-688C33CB-136E-4598-9487-F569FC94548E
P2860
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@en
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@nl
type
label
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@en
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@nl
prefLabel
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@en
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@nl
P2093
P2860
P356
P1476
Adduct-specific monoclonal ant ...... ons in individual cell nuclei.
@en
P2093
Bernd Liedert
Dick Pluim
Jan Schellens
Jürgen Thomale
P2860
P356
10.1093/NAR/GKL051
P407
P577
2006-03-29T00:00:00Z